Lean Life Science announces participation of four major pharmaceutical companies in unique oncology development programme, ODP2
- Fully funded programme – in collaboration with Cancer Research Horizons – to accelerate development of high impact cancer innovations
- Support from across the global oncology ecosystem
- Accepting only a limited number of applicants for 7-9 March DISCOVER session
Alderley Edge, UK – 22 February 2023: Today Lean Life Science (LLS), an organisation dedicated to catalysing innovation in life science through partnership, formally announces the participation of four major pharmaceutical companies in its flagship ODP2 oncology development programme. Now accepting applications for Part 2: DISCOVER, ODP2 is open to all UK-based academics and early-stage companies with a defined oncology-focused innovation.
Special to ODP2, participants will be able to leverage R&D expertise from across the oncology ecosystem to build and refine their bespoke development project plans, a crucial stage in the successful journey from the bench to the patient for every oncology innovation.
For this fully funded programme, Lean Life Science has focused on bringing together a comprehensive network of outstanding global pharma companies, contract research organisations and a suite of experts in residence, all with hands-on oncology development experience. The objective of ODP2 is to identify, de-risk and catalyse commercially viable UK-based oncology innovations. With the goal of improving diagnosis and treatment of cancer.
Helping to maintain a sustainable flow of innovation in oncology, the agenda for 7-9 March three-day DISCOVER session includes a full day dedicated to 1:1 partnering sessions with the participating experts. There are also interactive panel sessions in which senior representatives from the pharma companies will provide guidance on how to prepare for success.
For more information on taking part in ODP2, visit: leanlifescience.com